From the FDA Drug Label
Carefully consider the potential benefits and risks of Ketorolac Tromethamine Tablets USP and other treatment options before deciding to use Ketorolac Tromethamine Tablets USP. Ketorolac Tromethamine Tablets USP are indicated for the short-term (≤ 5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting
The use of Toradol (Ketorolac) after a hysteroscopy for endometrial cancer is not directly contraindicated in the provided drug labels. However, caution is advised as the labels recommend careful consideration of the potential benefits and risks, and the use of the lowest effective dose for the shortest duration.
- Key considerations:
- The patient's overall health and medical history
- The potential for increased risk of adverse reactions with prolonged use
- The need for alternative analgesics if necessary 1
From the Research
Toradol (ketorolac) can be administered to a patient after a hysteroscopy for endometrial cancer, but it should be used with caution and careful consideration of the individual patient's circumstances, as NSAIDs like Toradol can increase the risk of bleeding, which may be a concern after hysteroscopy 2. The typical dose is 30 mg IV or 60 mg IM every 6 hours as needed for pain, not to exceed 120 mg per day or 5 days of use. However, it's crucial to consult with the patient's oncologist and surgeon before administering Toradol. Some key points to consider when deciding to use Toradol include:
- The patient's specific cancer treatment plan, overall health status, and other medications need to be taken into account 3.
- Alternative pain management options, such as acetaminophen or opioids, might be preferred in some cases.
- The decision to use Toradol should be based on a balance between effective pain control and minimizing potential risks, particularly in the context of recent surgery and ongoing cancer treatment 4.
- Recent studies have shown that hysteroscopy is a safe and effective diagnostic method for endometrial cancer, with no significant difference in overall survival or recurrence-free survival compared to dilatation and curettage 2.
- The use of Toradol should be carefully considered in the context of the patient's individual circumstances, including their risk of bleeding and other potential complications 5.